Yes相关蛋白在卵巢浆液性腺癌中的表达及其临床意义

doi:10.3877/cma.j.issn.2095-655X.2017.02.013

目的

探讨Yes相关蛋白(YAP)在卵巢浆液性腺癌中的表达及其与临床病理特征的关系。

方法

收集泰安市中心医院病理科2008年1月至2012年12月收治的、经病理学检查确诊的卵巢浆液性腺癌石蜡包埋存档蜡块120例、正常卵巢组织40例。采用免疫组织化学链霉素抗生物素蛋白-过氧化物酶连结法(SP)，检测其YAP的表达水平，分析其与临床病理学特征的关系。

结果

卵巢浆液性腺癌组YAP阳性率(69.27%，83/120)高于正常卵巢组织组(7.5%，3/40)(χ²＝45.89，P<0.01)。低级别(51.1%，23/45)与高级别(80.0%，60/75)卵巢浆液性腺癌组织中YAP阳性率比较，差异有统计学意义(χ²＝11.01，P<0.01)；Ⅰ～Ⅱ期(64.9%，63/97)与Ⅲ～Ⅳ期(86.9%，20/23)卵巢浆液性腺癌组织中YAP阳性率比较，差异有统计学意义(χ²＝6.44，P<0.01)；淋巴结转移者(88.9%，24/27)YAP的表达与无淋巴结转移者(63.4%，59/93)阳性率比较也差异有统计学意义(χ²＝6.35，P<0.01)。

结论

YAP可能参与了卵巢浆液性腺癌的发生和发展的过程；可能成为判断卵巢浆液性腺癌发生发展和评价预后的有效参考指标之一，对于卵巢浆液性腺癌的早期预测可能具有重要的临床意义。

关键词: 卵巢肿瘤, 腺癌, Yes相关蛋白

Objective

To investigate the expressive significance of yes-associated protein(YAP) and its relationship with clinical pathological features in ovarian serous Adenocarcinoma (OSAC).

Methods

Forty normal and 120 OSAC patients were enrolled, whose was ovarian tissue were confirmed by pathological examination in the Central Hospital of TaiAn from January 2008 to December 2012.The expression of YAP in 120 cases of OSAC and 40 cases of normal was detected by immunohistochemically Streptavidin-peroxidase(SP) method to analyze its relationship with the clinical pathological features.

Results

The positive rate of YAP was higher in OSAC group (69.2%, 83/120) than that in normal ovarian tissue(7.5%, 3/40) (χ²=45.89, P<0.01). In OSAC, the expression of YAP in low level group (51.1%, 23/45) was significantly different with the high level group (80.0%, 60/75) (χ²=11.01, P<0.01). The expression of YAP in stage Ⅲ and Ⅳ group(86.9%, 20/23) was significantly different from the stage Ⅰand Ⅱgroup(64.9%, 63/97) (χ²=6.44, P<0.01). The expression of YAP in group with lymph node metastasis(88.9%, 24/27) was also significantly different from that in group without lymph node metastasis(63.4%, 59/93) (χ²=6.35, P<0.01).

Conclusions

YAP may participate in the process of occurrence and progression in OSAC.Detection of YAP may be an effective parameter in evaluating occurrence, progression and prognosis of OSAC, and may play an important role in early prediction of OSAC.

Key words: Ovarian neoplasms, Adenocarinoma, Yes-associated protein

表1 卵巢浆液性腺癌及正常卵巢组织中YAP蛋白表达情况比较(例数)

组别	总例数	阳性	阴性
卵巢浆液性腺癌组	120	83	37
正常卵巢组织组	40	3	37
χ²值	?	45.89	?
P值	?	0.000	?

表1 卵巢浆液性腺癌及正常卵巢组织中YAP蛋白表达情况比较(例数)

组别	总例数	阳性	阴性
卵巢浆液性腺癌组	120	83	37
正常卵巢组织组	40	3	37
χ²值	?	45.89	?
P值	?	0.000	?

表2 卵巢浆液性腺癌不同临床病理情况的YAP表达(例数)

病理特征		总例数	阳性	阴性	χ²值	P值
分化程度		?	?	?	11.01	0.001
?	低级别	45	23	22	?	?
?	高级别	75	60	15	?	?
淋巴结转移		?	?	?	6.35	0.012
?	有	27	24	3	?	?
?	无	93	59	34	?	?
TNM分期		?	?	?	6.44	0.040
?	Ⅰ～Ⅱ期	97	63	34	?	?
?	Ⅲ～Ⅳ期	23	20	3	?	?

表2 卵巢浆液性腺癌不同临床病理情况的YAP表达(例数)

病理特征		总例数	阳性	阴性	χ²值	P值
分化程度		?	?	?	11.01	0.001
?	低级别	45	23	22	?	?
?	高级别	75	60	15	?	?
淋巴结转移		?	?	?	6.35	0.012
?	有	27	24	3	?	?
?	无	93	59	34	?	?
TNM分期		?	?	?	6.44	0.040
?	Ⅰ～Ⅱ期	97	63	34	?	?
?	Ⅲ～Ⅳ期	23	20	3	?	?

[1]	王海燕,彭李博,王建军, 等. EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义[J]. 临床肿瘤学杂志, 2014, 19(11): 996-999.
[2]	李道胜,班媛媛. 卵巢伴微浸润的浆液性交界性肿瘤临床病理学特征分析[J/CD]. 中华诊断学电子杂志, 2016, 4(2): 116-119.
[3]	Liu M,Zhao S,Lin Q, et al.YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues[J]. Mol Cell Biol, 2015, 35(8): 1449-1461.
[4]	Greenspan DL,Connolly DC,Wu R, et al.Loss of FHIT expression in cervical carcinoma cell lines and primary tumors[J]. Cancer Res, 1997, 57(21): 4692-4698.
[5]	Dong J,Feldmann G,Huang J, et al.Elucidation of a universal size-control mechanism in drosophila and mammals[J]. Cell, 2007, 130(6): 1120－1133.
[6]	Lamar JM,Stern P,Liu H, et al.The hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain[J]. Proc Natl Acad Sci U S A, 2012, 109(37): E2441-2450.
[7]	Liu YC,Wang YZ.Role of Yes-associated protein 1 in gliomas：pathologic and therapeutic aspects[J]. Tumour Biol, 2015, 36(4): 2223-2227.
[8]	Cao JJ,Zhao XM,Wang DL, et al.YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis[J]. Oncol Rep, 2014, 32(4): 1594-1600.
[9]	Zhang L,Yang S,Chen X, et al.The hippo pathway effector, YAP, regulates motility, invasion and castration-resistant growth of prostate cancer cells[J]. Mol Cell Biol, 2015, 35(8): 1350-1362.
[10]	Guo J,Kleeff J,Zhao Y, et al. Yes-associated protein(YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma[J]. Int J Mol Med, 2006, 17(5): 761-767.
[11]	Steinhardt AA,Gayyed MF,Klein AP, et al. Expression of Yes-associated protein in common solid tumors[J]. Hum Pathol, 2008, 39(11): 1582-1589.
[12]	Zhang X,George J,Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene[J]. Oncogene, 2011, 30(25): 2810-2822.
[13]	Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
[14]	Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
[15]	Kim JM,Kang DW,Long LZ, et al. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma[J]. Hum Pathol, 2011, 42(3): 315-323.
[16]	Zhou Z,Zhu JS,Xu ZP.TRNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901[J]. Hepatogastroenterology, 2011, 58(112): 2156-2161.
[17]	Tsujiura M,Mazack V,Sudol M, et al.Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer[J]. PLoS One, 2014, 9(6): e100974.
[18]	Hall CA,Wang R,Miao J, et al. Hippo pathway effector Yap is an ovarian cancer oncogene[J]. Cancer Res, 2010, 70(21): 8517-8525.
[19]	He C,Lv X,Hua G, et al.YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression[J]. Oncogene, 2015, 34(50): 6040-6054.
[20]	Yoshikawa K,Noguchi K,Nakano Y, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma[J]. Int J Oncol, 2015, 46(6): 2364-2370.

[1]	邵华, 那子悦, 荆慧, 李博, 王秋程, 程文. 术前经皮超声造影对乳腺癌腋窝前哨淋巴结转移及负荷的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 849-853.
[2]	张旭, 徐建平, 苏冬明, 王彩芬, 王大力, 张文智. 男性乳腺肿块的超声造影特征[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 854-859.
[3]	方晔, 谢晓红, 罗辉. 品管圈在提高前列腺癌穿刺检出率中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 722-727.
[4]	孙帼, 谢迎东, 徐超丽, 杨斌. 超声联合临床特征的列线图模型预测甲状腺乳头状癌淋巴结转移的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 734-742.
[5]	康一坤, 袁芃. 三阴性乳腺癌分子遗传学及临床特征研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 290-293.
[6]	林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[7]	尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[8]	马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[9]	冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[10]	栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[11]	李全喜, 唐辉军, 张健生, 杨飞. 基于MUSE-DWI与SS-DWI技术在前列腺癌图像中的对比研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 553-557.
[12]	梅津熠, 王燕, 瞿旻, 董振阳, 周增辉, 沈显琦, 李嘉伦, 高旭. 机器人前列腺癌根治术中"膀胱外中叶"的处理[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 429-433.
[13]	刘飞, 王影新, 马骍, 辛灵, 程元甲, 刘倩, 王悦, 张军军. 不同介质腔内心电图定位技术在乳腺癌上臂输液港植入术中应用的随机对照研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 760-764.
[14]	岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[15]	王苏贵, 皇立媛, 姜福金, 吴自余, 张先云, 李强, 严大理. 异质性细胞核核糖蛋白A2B1在前列腺癌中的作用及其靶向中药活性成分筛选研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 731-736.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

The expression of yes-associated protein in ovarian serous adenocarcinoma and clinical significance

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

The expression of yes-associated protein in ovarian serous adenocarcinoma and clinical significance